Serum Vascular Endothelial Growth Factor-A (VEGF-A) as a Biomarker in Squamous Cell Carcinoma of Head and Neck Patients Undergoing Chemoradiotherapy

Srivastava, Vikas; Gara, Rishi K.; Rastogi, Namrata; Ahmed, Mohd Kaleem; Gupta, Shalini; Goel, Madhu Mati; Bhatt, Madan Lal Brahma

doi:10.7314/apjcp.2014.15.7.3261

Cited by 16 publications

(20 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Blood is a relatively stable body fluid; several serum protein markers have traditionally been used to help predict outcomes in HNSCC patients, including CDK4, midkines, tumor necrosis factor (TNF)‐like weak inducer of apoptosis (TWEAK), IL‐2R, and VEGF‐A . However, some are not always cancer‐specific, giving rise to problems in distinguishing between malignant and inflammatory disease …”

Section: Biomarkers From Liquid Biopsiesmentioning

confidence: 99%

“…More recently, markers from liquid biopsies that are directly related to cancer cells or cancer‐produced molecules have been employed, including circulating tumor cells (CTCs), cell‐free DNA (cfDNA)/circulating tumor DNA (ctDNA), cfRNA, and exosomes . It is generally accepted that CTCs may play an important role in cancer metastasis .…”

Section: Biomarkers From Liquid Biopsiesmentioning

confidence: 99%

“…Blood is a relatively stable body fluid; several serum protein markers have traditionally been used to help predict outcomes in HNSCC patients, including CDK4, 154 midkines, 178 tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK), 187 IL-2R, 186 and VEGF-A. 188 However, some are not always cancer-specific, giving rise to problems in distinguishing between malignant and inflammatory disease. [189][190][191][192] More recently, markers from liquid biopsies that are directly related to cancer cells or cancer-produced molecules have been employed, including circulating tumor cells (CTCs), 147,[150][151][152][153][154][155][156][157][158][159][160][161][162][163][164]193,194 cell-free DNA (cfDNA)/ circulating tumor DNA (ctDNA), [187][188][189][190][191][192]195,196 cfRNA, 184 and exosomes.…”

Section: Biomarkers From Liquid Biopsiesmentioning

confidence: 99%

See 2 more Smart Citations

Review of emerging biomarkers in head and neck squamous cell carcinoma in the era of immunotherapy and targeted therapy

Hsieh

Wang

et al. 2019

Head & Neck

View full text Add to dashboard Cite

Background Biomarkers in head and neck squamous cell carcinoma (HNSCC) emerge rapidly in recent years, especially for new targeted therapies and immunotherapies. Methods Recent, relevant peer‐reviewed evidence were critically reviewed and summarized. Results This review article briefly introduces essential biomarker concepts, including purposes and classifications (predictive, prognostic, and diagnostic markers), and the phases of biomarker development. We summarize current biomarkers in order of clinical utility; p16 and human papillomavirus status remain the most important and validated biomarkers in HNSCC. The rationale for biomarker study design continues to evolve with technological advances, especially whole‐exome or whole‐genomic sequencing. Noninvasive body fluid and liquid biopsy biomarkers appear to hold strong potential for development as tools for early cancer detection, cancer diagnosis, monitoring of disease recurrence, and outcome prediction. In light of discrepancies among different technologies, standardized approaches are needed. Conclusion Biomarkers from cancer tissue or blood in HNSCC could direct new anticancer therapies.

show abstract

Section: Biomarkers From Liquid Biopsiesmentioning

confidence: 99%

Section: Biomarkers From Liquid Biopsiesmentioning

confidence: 99%

Section: Biomarkers From Liquid Biopsiesmentioning

confidence: 99%

See 1 more Smart Citation

Review of emerging biomarkers in head and neck squamous cell carcinoma in the era of immunotherapy and targeted therapy

Hsieh

Wang

et al. 2019

Head & Neck

View full text Add to dashboard Cite

show abstract

“…Interestingly, up-regulation of VEGFA is also associated with lethal hepatic syndrome (Chen et al, 2014), gastric (Liu et al, 2011), lungs (Jin et al, 2011Zhang et al, 2014), ovarian (Khemapech et al, 2012) pancreatic (Tang et al, 2006) head and neck (Srivastava et al, 2014), thyroid papillary carcinoma (Klein et al, 2001), myeloid tumors (Stockman et al, 2008;Kim et al, 2009), breast cancer (Schneider et al, 2010;Zhang et al, 2013), medulloblastoma (Pereira et al, 2010), osteosarcoma (Zhu et al, 2010), bladder (Chen et al, 2012;Pignot et al, 2009), colorectal cancer (Sheffer et al, 2009) myeloma (Vlajnic et al, 2010) and glioblastoma (Hose et al, 2009). Although no significant association of VEGF with hormone receptors (ER, PR and HER status) has been established, yet a strong prognostic correlation in relation to mammary, prostate, hepatic, head and neck tumors had been established (Ryden et al, 2005;Yu et al, 2010;Xu et al, 2013;Srivastava et al, 2014). Hence a consistent finding of VEGFA over expression in majority of cancer strongly suggests it prognostic significance when analyzed with other markers.…”

Section: Effect Of Vegfa In Cancermentioning

confidence: 99%

Diagnostic and Therapeutic Implications of the Vascular Endothelial Growth Factor Family in Cancer

Riaz

Iqbal²,

Malik

2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Cancer progression is attained by uncontrolled cell division and metastasis. Increase in tumor size triggers different vascular channel formation to address cell nutritional demands. These channels are responsible for transferring of nutrients and gaseous to the cancer cells. Cancer vascularization is regulated by numerous factors including vascular endothelial growth factors (VEGFs). These factors play an important role during embryonic development. Members included in this group are VEGFA, VEGFB, VEGFC, PIGF and VEGFD which markedly influence cellular growth and apoptosis. Being freely diffusible these proteins act in both autocrine and paracrine fashions. In this review, genetic characterization these molecules and their putative role in cancer staging has been elaborated. Prognostic significance of these molecules along with different stages of cancer has also been summarized. Brief outline of ongoing efforts to target hot spot target sites against these VEGFs and their cognate limitations for therapeutic implications are also highlighted.

show abstract

“…It is the result of an intricate balance between pro-angiogenic and anti-angiogenic factors (Srivastava et al, 2014). The VEGF family is composed of several subtypes, including VEGF-A, VEGF-B, VEGF-C, and VEGF-D which exist as numerous splice variant isoforms (Sugiura et al, 2009).…”

Section: Introductionmentioning

confidence: 99%

Novel DOX-MTX Nanoparticles Improve Oral SCC Clinical Outcome by Down Regulation of Lymph Dissemination Factor VEGF-C Expression in vivo: Oral and IV Modalities

Abbasi

Amir²,

Hamishehkar³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Oral squamous cell carcinoma (OSCC) remains as one of the most difficult malignancies to control because of its high propensity for local invasion and cervical lymph node dissemination. The aim of present study was to evaluate the efficacy of novel pH and temperature sensitive doxorubicin-methotrexateloaded nanoparticles (DOX-MTX NP) in terms of their potential to change the VEGF-C expression profile in a rat OSCC model. Materials and Methods: 120 male rats were divided into 8 groups of 15 animals administrated with 4-nitroquinoline-1-oxide to induce OSCCs. Newly formulated doxorubicin-methotrexate-loaded nanoparticles (DOX-MTX NP) and free doxorubicin were IV and orally administered. Results: Results indicated that both oral and IV forms of DOX-MTX-nanoparticle complexes caused significant decrease in the mRNA level of VEGF-C compared to untreated cancerous rats (p<0.05) . Surprisingly, the VEGF-C mRNA was not affected by free DOX in both IV and oral modalities (p>0.05). Furthermore, in DOX-MTX NP treated group, less tumors characterized with advanced stage and VEGF-C mRNA level paralleled with improved clinical outcome (p<0.05). In addition, compared to untreated healthy rats , the VEGF-C expression was not affected in healthy groups that were treated with IV and oral dosages of nanodrug (p>0.05). Conclusions: VEGF-C is one of the main prognosticators for lymph node metastasis in OSCC. Down-regulation of this lymph-angiogenesis promoting factor is a new feature acquired in group treated with dual action DOX-MTX-NPs. Beside the synergic apoptotic properties of concomitant use of DOX and MTX on OSCC, DOX-MTX NPs possessed anti-angiogenesis properties which was related to the improved clinical outcome in treated rats. Taking together, we conclude that our multifunctional doxorubicin-methotrexate complex exerts specific potent apoptotic and anti-angiogenesis properties that could ameliorate the clinical outcome presumably via down-regulating dissemination factor-VEGF-C expression in a rat OSCC model.

show abstract

Serum Vascular Endothelial Growth Factor-A (VEGF-A) as a Biomarker in Squamous Cell Carcinoma of Head and Neck Patients Undergoing Chemoradiotherapy

Cited by 16 publications

References 46 publications

Review of emerging biomarkers in head and neck squamous cell carcinoma in the era of immunotherapy and targeted therapy

Review of emerging biomarkers in head and neck squamous cell carcinoma in the era of immunotherapy and targeted therapy

Diagnostic and Therapeutic Implications of the Vascular Endothelial Growth Factor Family in Cancer

Novel DOX-MTX Nanoparticles Improve Oral SCC Clinical Outcome by Down Regulation of Lymph Dissemination Factor VEGF-C Expression in vivo: Oral and IV Modalities

Contact Info

Product

Resources

About